Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

A meta-research study revealed several challenges in obtaining placebos for investigator-initiated drug trials

Graphical Abstract Sample Work

Investigator-initiated drug trials (IITs) are essential for advancing independent, hypothesis-driven clinical research and addressing unmet therapeutic questions. However, conducting randomized controlled trials frequently requires access to matching placebos to ensure methodological rigor and minimize bias. Obtaining suitable placebos remains a significant logistical, regulatory, and financial challenge, particularly in non-industry-sponsored research. Barriers such as manufacturing constraints, intellectual property restrictions, regulatory approval processes, and limited commercial incentives can delay or compromise trial execution. This meta-research study evaluates the scope, nature, and impact of placebo procurement challenges in investigator-initiated drug trials and explores potential strategies to overcome these barriers.

Mapping a procurement problem rather than a biological one

Most graphical abstracts depict disease mechanisms or clinical outcomes. This one depicts research logistics. It summarises a meta-research study by Speich and colleagues for the MAking Randomized Trials Affordable (MARTA) Group, published in the Journal of Clinical Epidemiology in 2021, which examined how investigators running independent drug trials obtain placebos and what problems they encounter. The audience includes trialists, clinical trial units, research funders, ethics committees and pharmaceutical companies that receive placebo requests.

The figure places a "Corresponding author/Investigator" icon at the top centre and arranges the rest of the evidence around the routes that investigator can take to obtain placebos.

Why placebos are hard to obtain for investigator-initiated trials

Investigator-initiated trials (IITs) are designed and run by academic or clinical researchers rather than by industry. They answer questions that commercial sponsors may not prioritise, such as comparing established drugs or testing new uses for older ones. Placebo-controlled designs protect against bias by enabling blinding of participants and assessors, but a placebo must match the active drug in appearance, taste and packaging to work properly.

Industry sponsors manufacture matching placebos alongside their products. Independent investigators often cannot. They must ask the manufacturer, which may decline, or find another source, which costs money and may not achieve a convincing match. Meta-research, the study of how research itself is conducted, is well suited to quantifying these barriers across many trials.

The upper half: routes, refusals and consequences

Two green arrows rise towards the investigator from two boxes: 79 trials obtained placebos from other sources, and 28 obtained them from the drug manufacturer, of which 19 (68%) said the manufacturer wanted to see the study protocol. A red, downward arrow with a prohibition sign shows that 22 of the investigators who obtained placebos elsewhere had first approached the manufacturer unsuccessfully. Their reasons are listed: 7 could not provide, 6 had no interest, 4 cited excessive costs, 3 cited expired patents, and 2 wished to avoid conflicts of interest.

At top left, a purple box headed "Conduct of trial" records the most serious consequences: 6% (6 of 101) of investigators had already cancelled a trial because of a lack of placebos, and 27% (27 of 101) had adapted a trial's design because matching placebos were unavailable.

The lower band: sources, costs, matching and industry interest

A pale yellow band across the bottom divides into three columns.

  • Other sources. Hospital pharmacies (n=32), other manufacturers (n=19), other pharmacies (n=15) and other sources (n=13). Matching was achieved using capsules (n=25), saline (n=22), similar or matching tablets (n=17) and other methods (n=15).
  • Placebos. The median cost was US$58,286 per trial, representing 10.3% of trial budgets (n=24). Twenty-one of 102 investigators used non-matching placebos, and only one publication labelled them correctly.
  • Drug manufacturer/industry. Asked whether the trial hypothesis was in the manufacturer's interest, 49 of 101 (48%) answered yes, 29 of 101 (28%) no, and 23 of 101 (23%) were unsure or did not answer. In the manufacturer column, 47% of the yes group obtained drugs and 37% obtained placebos, compared with 17% for each in the no group.

The final comparison is the study's most pointed finding: manufacturer support appears more likely when the research question aligns with commercial interest.

Handling many denominators accurately

This figure contains more numbers than most graphical abstracts, and the denominators differ (101, 102, 24). Reproducing each count with its own denominator, as the sample does, avoids the common error of presenting percentages from different subsets as if they shared a base. Superscript markers (a, b) are retained from the source to point readers to footnotes in the paper. The conclusion, set in a dark box at bottom right, argues that addressing barriers to placebo access is essential to support independent trials and promote unbiased evidence. Trials that do use placebos should describe them as CONSORT recommends, including how similar they were to the active intervention.

When a data-dense layout is the right choice

For meta-research and survey studies, where the findings are counts and proportions rather than one effect size, a flow arrangement with boxed figures can work better than charts. Group results by stage of the process, keep denominators visible and use colour to separate success from refusal. Pubrica's graphical abstract service designs figures for methodological papers as well as clinical ones, and investigators planning an independent trial can address placebo and blinding strategy early through experimental design support.

Questions about this sample

Why did investigators who approached manufacturers fail to obtain placebos?

Among the 22 investigators who approached manufacturers unsuccessfully before finding another source, 7 were told the company could not provide placebos, 6 met no interest, 4 found costs too high, 3 were affected by expired patents, and 2 were refused because the company wished to avoid conflicts of interest.

How much did placebos add to the cost of an independent trial?

Among the 24 trials with cost data, the median cost of placebos was US$58,286 per trial, which represented 10.3% of the trial budget. For publicly funded studies with limited budgets, this is a substantial share, and it helps explain why some investigators adapted or cancelled their trials.

What does the comparison of industry interest show?

In the drug manufacturer column, when investigators judged the trial hypothesis to be in the manufacturer's interest, 47% obtained drugs and 37% obtained placebos. When the hypothesis was not in its interest, both figures were 17%. This suggests that independent questions that do not suit commercial priorities face greater difficulty obtaining materials.

pubrica services with experts

Research your Services with our experts

Delivered on-time or your money back

Give yourself the academic edge today

Each order includes

  • On-time delivery or your money back
  • A fully qualified writer in your subject
  • In-depth proofreading by our Quality Control Team
  • 100% confidentiality, the work is never re-sold or published
  • Standard 7-day amendment period
  • A paper written to the standard ordered
  • A detailed plagiarism report
  • A comprehensive quality report

Enquire Now

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.